Procept BioRobotics announced today that the first patients were treated in its Water II Study, a clinical trial testing the safety and efficacy of Aquablation delivery by its surgical robotic AquaBeam System to treat benign prostatic hyperplasia. The trials test the use of the system in prostates 80 to150 mL and will enroll 100 patients […]
Procept BioRobotics
7 medtech stories we missed this week: May 26, 2017
From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. […]
Procept BioRobotics launches AquaBeam trial
Procept BioRobotics said today it treated the 1st patients in a clinical trial of its AquaBeam water ablation therapy system designed to treat prostate disease. The Water study is a phase III clinical study evaluating the safety and effectiveness of the system compared to transurethral resection of the prostate, the current standard of care for […]
Procept BioRobotics closes $42m round for AquaBeam prostate device
Procept BioRobotics said today that it closed on a $42 million round for its AquaBeam “waterjet ablation” device for treating prostate cancer. Redwood Shores, Calif.-based Procept said the round was led by Novo Nordisk’s (NYSE:NVO) investment arm, Novo A/S, with new backer CPMG and existing investors also contributing. The AquaBeam device uses a high-pressure water jet […]